Abstract
A total of 1,537 clinical isolates of Haemophilus influenzae were recovered in 30 U.S. medical center laboratories between 1 November 1994 and 30 April 1995 and were characterized in a central laboratory with respect to serotype and beta-lactamase production and the in vitro activities of 15 oral antimicrobial agents. Overall, 36.4% of the isolates were found to produce beta-lactamase. The rank order of activity of six cephalosporins on the basis of MICs was cefixime > cefpodoxime > cefuroxime > loracarbef > or = cefaclor > cefprozil. On the basis of current National Committee for Clinical Laboratory Standards (NCCLS) breakpoints ages of isolates found to be resistant or intermediate to these agents were as follows: 0.1, 0.3, 6.4, 16.3, 18.3, and 29.8, respectively (National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. M7-A4, 1995). Azithromycin was, on a weight basis, the most potent of the macrolides tested in this study, followed by erythromycin and then clarithromycin. Azithromycin was typically fourfold more active than erythromycin, which was, in turn, slightly more active than clarithromycin. However, when compared on the basis of the frequency of resistance determined by using current NCCLS breakpoints, there was essentially no difference between azithromycin and clarithromycin, i.e., 0.5 and 1.9%, respectively (P = 0.086). Interpretive breakpoints for erythromycin MIC tests versus H. influenzae have not been developed. Resistance to other non- beta-lactam agents was variable, as follows: trimethoprim-sulfamethoxazole, 9.0%; chloramphenicol, 0.2%; tetracycline, 1.3%; and rifampin, 0.3%. Two conspicuous findings in this study were the identification of 39 strains H. influenzae that were beta-lactamase negative but ampicillin intermediate or resistant (BLNAR) and, even more surprisingly, 17 beta-lactamase-positive isolates that were resistant to amoxicillin-clavulanate (BLPACR). Strains of H. influenzae in the first group have heretofore been very uncommon; organisms in the second group have not previously been described in the literature. The percentages of all study isolates comprised of BLNAR and BLPACR organisms were 2.5 and 1.1, respectively. Overall resistance to ampicillin was thus 38.9%, and that to amoxicillin-clavulanate was 4.5%.
MeSH Terms
Adolescent
Adult
Amoxicillin/pharmacology
Amoxicillin-Potassium Clavulanate Combination
Anti-Bacterial Agents/pharmacology
Child
Child, Preschool
Clavulanic Acids/pharmacology
Drug Resistance, Microbial
Drug Resistance, Multiple
Drug Therapy, Combination/pharmacology
Female
Haemophilus influenzae/drug effects,enzymology,isolation & purification
Humans
Male
Microbial Sensitivity Tests
Middle Aged
beta-Lactamases/metabolism
Chemicals
Anti-Bacterial Agents
Clavulanic Acids
Amoxicillin-Potassium Clavulanate Combination
Amoxicillin
beta-Lactamases
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Doern G V
Clinical Microbiology Laboratories, University of Massachusetts, Worcester 01655, USA.
Brueggemann A B
Pierce G
Holley H P
Rauch A
References (24)
24 references, click to expand
-
Broth microdilution testing of Haemophilus influenzae with haemophilus test medium versus lysed horse blood broth. Canadian Haemophilus Study Group.
J Clin Microbiol. 1992 Sep;30(9):2284-9
PMID: 1400992
-
Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group.
Pediatr Infect Dis J. 1992 Aug;11(8):610-3
PMID: 1523069
-
In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.
Antimicrob Agents Chemother. 1994 Oct;38(10):2419-25
PMID: 7840581
-
A survey of beta-lactamase-producing Haemophilus influenzae. An evaluation of 5750 isolates.
Diagn Microbiol Infect Dis. 1995 Apr;21(4):223-5
PMID: 7554806
-
Ampicillin-resistant Haemophilus influenzae type B infection.
JAMA. 1974 Jul 15;229(3):295-7
PMID: 4546093
-
Haemophilus influenzae type B resistant to ampicillin. A report of two cases.
JAMA. 1974 Jul 15;229(3):298-301
PMID: 4546094
-
Chromogenic cephalosporin spot test to detect beta-lactamase in clinically significant bacteria.
J Clin Microbiol. 1979 Feb;9(2):205-7
PMID: 34624
-
Isolation of an ampicillin-resistant, non-beta-lactamase-producing strain of Haemophilus influenzae.
Antimicrob Agents Chemother. 1980 Jan;17(1):80-3
PMID: 6965443
-
Mechanisms of ampicillin resistance in Haemophilus influenzae from respiratory tract.
Lancet. 1980 Feb 9;1(8163):279-80
PMID: 6101737
-
Ampicillin treatment failure of apparently beta-lactamase-negative Haemophilus influenzae type b meningitis due to novel beta-lactamase.
Lancet. 1981 Nov 7;2(8254):1008-10
PMID: 6118476
-
Mechanism of resistance of an ampicillin-resistant, beta-lactamase-negative clinical isolate of Haemophilus influenzae type b to beta-lactam antibiotics.
Antimicrob Agents Chemother. 1984 Jun;25(6):747-53
PMID: 6611136
-
Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae.
Antimicrob Agents Chemother. 1984 Aug;26(2):235-44
PMID: 6333208
-
Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study.
Diagn Microbiol Infect Dis. 1986 Feb;4(2):95-107
PMID: 3485505
-
An animal source for the ROB-1 beta-lactamase of Haemophilus influenzae type b.
Antimicrob Agents Chemother. 1986 Feb;29(2):212-5
PMID: 3487284
-
Cloning and expression of genes responsible for altered penicillin-binding proteins 3a and 3b in Haemophilus influenzae.
Antimicrob Agents Chemother. 1987 Feb;31(2):286-91
PMID: 3551833
-
Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.
J Clin Microbiol. 1987 Nov;25(11):2105-13
PMID: 3500965
-
National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae.
Antimicrob Agents Chemother. 1988 Feb;32(2):180-5
PMID: 3259121
-
Sequence analysis and evolutionary perspectives of ROB-1 beta-lactamase.
Antimicrob Agents Chemother. 1990 Jul;34(7):1354-9
PMID: 2201253
-
Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.
Antimicrob Agents Chemother. 1990 Jul;34(7):1407-13
PMID: 2143642
-
Susceptibility of Haemophilus influenzae to antimicrobial agents used in Canada. Canadian Study Group.
CMAJ. 1990 Nov 1;143(9):895-901
PMID: 2224717
-
Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.
Antimicrob Agents Chemother. 1990 Nov;34(11):2075-80
PMID: 2127342
-
Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae.
Clin Infect Dis. 1992 May;14(5):1119-23
PMID: 1600014
-
Molecular basis of the non-beta-lactamase-mediated resistance to beta-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada.
Antimicrob Agents Chemother. 1992 Jul;36(7):1504-13
PMID: 1510447
-
Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. Canadian Haemophilus Study Group.
Antimicrob Agents Chemother. 1994 Jul;38(7):1678-80
PMID: 7979309